Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

Expert Opinion on Drug Delivery

Volumn 9, Issue 11, 2012, Pages 1319-1323

  Garay, Ricardo P ^a   El Gewely, Raafat ^b   Armstrong, Jonathan K ^c   Garratty, George ^d   Richette, Pascal ^e  

^a Universite Paris Sud   (France)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d AMERICAN RED CROSS BLOOD SERVICES   (United States)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Anti PEG; Antigenicity; Immunogenicity; PEGylated proteins; PEGylation; Polyethylene glycol

Indexed keywords

ALANINE; ANTIBODY; ASPARAGINASE MACROGOL; EPITOPE; EREPOXEN; ERYTHROPOIETIN; EXENDIN 4; GROWTH HORMONE; HYDROXYL GROUP; INSULIN; LIPOSOME; MACROGOL; MACROGOL ANTIBODY; PEGLOTICASE; POLYSIALIC ACID; PROLINE; SERINE; SULIXEN; UNCLASSIFIED DRUG; URATE OXIDASE; VRS 317; VRS 859;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BLOOD DONOR; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIZATION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; EXPERIMENTAL MODEL; GOUT; GROWTH HORMONE DEFICIENCY; HALF LIFE EXTENSION TECHNOLOGY; HUMAN; IMMUNOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PASYLATION; PEGYLATION; TECHNOLOGY;

ALLERGENS; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS; DRUG CARRIERS; HUMANS; POLYETHYLENE GLYCOLS;

EID: 84867760417     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.720969     Document Type: Article

References (36)

1. Payne RW, Murphy BM MM. Product development issues for PEGylated proteins. Pharm Dev Technol 2011;16:423-40
2. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-80
3. Omata D, Negishi Y, Hagiwara S, et al. Enhanced gene delivery using Bubble liposomes and ultrasound for folate-PEG liposomes. J Drug Target 2012;20(4): 355-63; Early Online [Feb 15]: 1-9
4. Chen C, Constantinou A, Deonarain M. Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opin Drug Deliv 2011;8:1221-36
5. Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. PEGylated protein drugs. Basic Science and Clinical Applications Basel; Birkhauser Verlag: 2009
6. Garay RP, Labaune JP. Immunogenicity of Polyethylene Glycol (PEG). The Open Conference Proceedings Journal; 2011. p. 2
7. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983;70:124-31 (Pubitemid 13171427)
8. Tsuji J, Hirose K, Kasahara E, et al. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Intl J Immunopharmacol 1985;7:725-30 (Pubitemid 16255837)
9. Wang XY, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007;119:236-44 (Pubitemid 46759557)
10. Semple SC, Harasym TO, Clow KA, et al. Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid. J Pharmacol Expl Ther 2005;312:1020-6 (Pubitemid 40293760)
11. Judge A, McClintock K PJ, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37 (Pubitemid 43056898)
12. Sroda K, Rydlewski J, Langner M, et al. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005;10:37-47 (Pubitemid 40559058)
13. Yang Z, Wang J, Lu Q, et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004;64:6673-8 (Pubitemid 39297929)
14. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: Titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984;74:36-9 (Pubitemid 14136479)
15. Tillmann H, Ganson NJ, Patel K, et al. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-Interferon. J Hepatol 2010;52(Suppl 1):S129-S
16. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-11 (Pubitemid 46986423)
17. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011;306:711-20
18. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008;46:225-32
19. Andersson L DJ, Duncan R FP, Ford J, et al. Poly(ethylene glycol)-poly(estercarbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 2005;6:914-26 (Pubitemid 40467837)
20. Garay RP, El-Gewely MR, Labaune J-P, Richette P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012;79:237-42
21. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68 (Pubitemid 350186186)
22. 3SBio. 3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million. The Medical News: News-Medical. Net; 2010
23. da Silva Freitas D, Spencer PJ, Vassao RC, Abrahao-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm 2010;387:215-22
24. Tan QY, Wang N, Yang H, et al. Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm 2010;384:165-72
25. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci (USA) 1989;86:9412-16 (Pubitemid 20010436)
26. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. In: El-Gewely MR, editor. Biotechnology annual review. Elsevier, Amsterdam; 2008. p. 191-202
27. El-Gewely MR, Fenton C, Kjeldsen E, Xu H. Mutagenesis: site-specific encyclopedia of life sciences. Nature Publishing Group & Wiley, Chichester (UK); 2005. p. 1-12
28. Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 2008;94:87; 27-95
29. Armstrong JK, Meiselman HJ, Fisher TC. Covalent binding of poly (ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity. Am J Hematol 1997;56:26-8 (Pubitemid 27398054)
30. Sherman MR, Williams LD, Sobczyk MA, et al. Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates. Bioconjug Chem 2012;23:485-99
31. Sherman MR, Saifer MGP, David Williams L, et al. Next-generation PEGylation enables reduced immunoreactivity of PEG-protein conjugates. Drug Dev Del 2012;12:36-42
32. Geething NC, To W, Spink BJ, et al. Gcg-XTEN: An improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS One 2010;5:e10175
33. Amunix. Available from: www.amunix. com [Accessed 8 August 12]
34. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22(6):868-76
35. Available from: xl-protein. com (Accessed 08 August 12)
36. XL-protein. Available from: xl-protein. com (Accessed 08 August 12) 36. Pasut G, Veronese FM. State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release 2011; [Epub ahead of print]